## Annette Haworth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7842712/publications.pdf

Version: 2024-02-01

201674 223800 2,546 118 27 46 citations h-index g-index papers 119 119 119 2448 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A review of medical image data augmentation techniques for deep learning applications. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 545-563.	1.8	297
2	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG) Tj ETQq0 0 0 rgB 2020, 21, 1331-1340.	T /Overloc 10.7	k 10 Tf 50 7 197
3	Online Adaptive Radiotherapy for Muscle-Invasive Bladder Cancer: Results of a Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 765-771.	0.8	108
4	A <scp>P</scp> hase <scp>III</scp> trial to investigate the timing of radiotherapy for prostate cancer with highâ€risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage ( <scp>RAVES</scp> ) trial. BJU International, 2014, 113, 7-12.	2.5	104
5	Multiparametric MRI and radiomics in prostate cancer: a review. Australasian Physical and Engineering Sciences in Medicine, 2019, 42, 3-25.	1.3	87
6	Intra-fraction prostate displacement in radiotherapy estimated from pre- and post-treatment imaging of patients with implanted fiducial markers. Radiotherapy and Oncology, 2010, 95, 191-197.	0.6	75
7	Detailed review and analysis of complex radiotherapy clinical trial planning data: Evaluation and initial experience with the SWAN software system. Radiotherapy and Oncology, 2008, 86, 200-210.	0.6	70
8	A generic high-dose rate < sup > 192 < /sup > Ir brachytherapy source for evaluation of model-based dose calculations beyond the TG-43 formalism. Medical Physics, 2015, 42, 3048-3062.	3.0	64
9	Comparison of DVH data from multiple radiotherapy treatment planning systems. Physics in Medicine and Biology, 2010, 55, N337-N346.	3.0	60
10	Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2015, 115, 301-307.	0.6	52
11	Offline adaptive radiotherapy for bladder cancer using cone beam computed tomography. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 226-233.	1.8	49
12	Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 693-702.	0.8	48
13	Development of a registration framework to validate MRI with histology for prostate focal therapy. Medical Physics, 2015, 42, 7078-7089.	3.0	45
14	Global Harmonization of Quality Assurance Naming Conventions in Radiation Therapy Clinical Trials. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1242-1249.	0.8	44
15	Source position verification and dosimetry in HDR brachytherapy using an EPID. Medical Physics, 2013, 40, 111706.	3.0	39
16	Development and evaluation of a training program for therapeutic radiographers as a basis for online adaptive radiation therapy for bladder carcinoma. Radiography, 2010, 16, 14-20.	2.1	38
17	Interâ€observer variability of clinical target volume delineation for bladder cancer using CT and cone beam CT. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 100-106.	1.8	36
18	Quality improvements in prostate radiotherapy: Outcomes and impact of comprehensive quality assurance during the <scp>TROG</scp> 03.04 â€~ <scp>RADAR</scp> ' trial. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 247-257.	1.8	36

#	Article	IF	CITATIONS
19	Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial. Radiotherapy and Oncology, 2015, 116, 112-118.	0.6	36
20	Assuring high quality treatment delivery in clinical trials – Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR―set-up accuracy study. Radiotherapy and Oncology, 2009, 90, 299-306.	0.6	35
21	Seminal vesicle interfraction displacement and margins in image guided radiotherapy for prostate cancer. Radiation Oncology, 2012, 7, 139.	2.7	35
22	A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer. Radiation Oncology, 2012, 7, 111.	2.7	35
23	A generic TGâ€186 shielded applicator for commissioning modelâ€based dose calculation algorithms for highâ€doseâ€rate <sup>192</sup> Ir brachytherapy. Medical Physics, 2017, 44, 5961-5976.	3.0	34
24	An integrated system for clinical treatment verification of HDR prostate brachytherapy combining source tracking with pretreatment imaging. Brachytherapy, 2018, 17, 111-121.	0.5	32
25	Gastrointestinal Dose-Histogram Effects in the Context of Dose-Volume–Constrained Prostate Radiation Therapy: Analysis of Data From the RADAR Prostate Radiation Therapy Trial. International Journal of Radiation Oncology Biology Physics, 2015, 91, 595-603.	0.8	31
26	Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. Brachytherapy, 2013, 12, 628-636.	0.5	30
27	Simple methods to reduce patient dose in a Varian cone beam CT system for delivery verification in pelvic radiotherapy. British Journal of Radiology, 2009, 82, 855-859.	2.2	29
28	Verification of target position in the postâ€prostatectomy cancer patient using cone beam CT. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 212-220.	1.8	29
29	Predicting prostate tumour location from multiparametric MRI using Gaussian kernel support vector machines: a preliminary study. Australasian Physical and Engineering Sciences in Medicine, 2017, 40, 39-49.	1.3	29
30	Dosimetry for audit and clinical trials: challenges and requirements. Journal of Physics: Conference Series, 2013, 444, 012014.	0.4	28
31	Quality Assurance for Clinical Trials. Frontiers in Oncology, 2013, 3, 311.	2.8	28
32	Prospective trial of intraoperative radiation treatment for breast cancer. ANZ Journal of Surgery, 2004, 74, 1043-1048.	0.7	25
33	Assessment of i-125 prostate implants by tumor bioeffect. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1405-1413.	0.8	25
34	Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 493-501.	0.6	24
35	Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. British Journal of Radiology, 2019, 92, 20190373.	2.2	23
36	A method for verification of treatment delivery in HDR prostate brachytherapy using a flat panel detector for both imaging and source tracking. Medical Physics, 2016, 43, 2435-2442.	3.0	20

#	Article	IF	Citations
37	ACPSEM brachytherapy working group recommendations for quality assurance in brachytherapy. Australasian Physical and Engineering Sciences in Medicine, 2013, 36, 387-396.	1.3	19
38	A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Radiotherapy and Oncology, 2014, 112, 187-193.	0.6	19
39	Voxel-wise prostate cell density prediction using multiparametric magnetic resonance imaging and machine learning. Acta Oncol $\hat{A}^3$ gica, 2018, 57, 1540-1546.	1.8	19
40	Prostate implant evaluation using tumour control probabilityâ€"the effect of input parameters. Physics in Medicine and Biology, 2004, 49, 3649-3664.	3.0	18
41	Understanding the Relationship Between Interactive Optimisation and Visual Analytics in the Context of Prostate Brachytherapy. IEEE Transactions on Visualization and Computer Graphics, 2018, 24, 319-329.	4.4	18
42	Rectal Filling at Planning Does Not Predict Stability of the Prostate Gland during a Course of Radical Radiotherapy if Patients with Large Rectal Filling are Re-imaged. Clinical Oncology, 2009, 21, 760-767.	1.4	16
43	A radiobiology-based inverse treatment planning method for optimisation of permanent l-125 prostate implants in focal brachytherapy. Physics in Medicine and Biology, 2016, 61, 430-444.	3.0	16
44	Optimised Robust Treatment Plans for Prostate Cancer Focal Brachytherapy. Procedia Computer Science, 2015, 51, 914-923.	2.0	15
45	Deforming to Best Practice: Key considerations for deformable image registration in radiotherapy. Journal of Medical Radiation Sciences, 2020, 67, 318-332.	1.5	15
46	Comparison of 192 Ir air kerma calibration coefficients derived at ARPANSA using the interpolation method and at the National Physical Laboratory using a direct measurement. Australasian Physical and Engineering Sciences in Medicine, 2008, 31, 332-338.	1.3	14
47	MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review. Expert Review of Anticancer Therapy, 2021, 21, 425-449.	2.4	14
48	Australasian brachytherapy audit: Results of the  endâ€ŧoâ€end' dosimetry pilot study. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 490-498.	1.8	13
49	Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: Results from the TROG 03.04 RADAR trial. Radiotherapy and Oncology, 2018, 126, 249-256.	0.6	13
50	Automatic stratification of prostate tumour aggressiveness using multiparametric MRI: a horizontal comparison of texture features. Acta Oncol $\tilde{A}^3$ gica, 2019, 58, 1118-1126.	1.8	13
51	Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans†asman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 390-398.	1.8	13
52	Dosimetry of a low-kV intra-operative X-ray source using basic analytical beam models. Australasian Physical and Engineering Sciences in Medicine, 2002, 25, 119-123.	1.3	12
53	Multicentre analysis of treatment planning information: Technical requirements, possible applications and a proposal. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 347-352.	0.6	12
54	<pre><scp>T</scp>rans <scp>T</scp>asman <scp>R</scp>adiation <scp>O</scp>ncology <scp>G</scp>roup: Development of the <scp>A</scp>ssessment of <scp>N</scp>ew <scp>R</scp>adiation <scp>O</scp>ncology <scp>T</scp>echnology and <scp>T</scp>reatments (<scp>ANROTAT</scp>) <scp>F</scp>ramework. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 363-370.</pre>	1.8	12

#	Article	IF	CITATIONS
55	A virtual dosimetry audit – Towards transferability of gamma index analysis between clinical trial QA groups. Radiotherapy and Oncology, 2017, 125, 398-404.	0.6	12
56	Impact of selection of post-implant technique on dosimetry parameters for permanent prostate implants. Brachytherapy, 2005, 4, 146-153.	0.5	11
57	Benchmarking Dosimetric Quality Assessment of Prostate Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 998-1005.	0.8	11
58	Comparison of TLD calibration methods for dosimetry. Journal of Applied Clinical Medical Physics, 2013, 14, 258-272.	1.9	11
59	Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1045-1051.	0.8	11
60	Tenâ€year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 531-538.	1.8	11
61	3D catheter reconstruction in HDR prostate brachytherapy for pre-treatment verification using a flat panel detector. Physica Medica, 2017, 39, 121-131.	0.7	10
62	Focal therapy for prostate cancer: the technical challenges. Journal of Contemporary Brachytherapy, 2017, 4, 383-389.	0.9	10
63	Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials. Frontiers in Oncology, 2020, 10, 1174.	2.8	10
64	Cell density in prostate histopathology images as a measure of tumor distribution. Proceedings of SPIE, $2014, $ , .	0.8	9
65	Voxelâ€wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International, 2019, 123, 1020-1030.	2.5	9
66	Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1304-1318.	0.8	9
67	Biologically Targeted Radiation Therapy: Incorporating Patient-Specific Hypoxia Data Derived from Quantitative Magnetic Resonance Imaging. Cancers, 2021, 13, 4897.	3.7	9
68	Prostate Bed Radiation Therapy: The Utility of Ultrasound Volumetric Imaging of the Bladder. Clinical Oncology, 2014, 26, 789-796.	1.4	8
69	A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy. Physics and Imaging in Radiation Oncology, 2022, 21, 136-145.	2.9	8
70	Prospective development of an individualised predictive model for treatment coverage using offline cone beam computed tomography surrogate measures in postâeprostatectomy radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 574-580.	1.8	7
71	Optimising the dosimetric quality and efficiency of postâ€prostatectomy radiotherapy: A planning study comparing the performance of volumetricâ€modulated arc therapy (VMAT) with an optimised sevenâ€field intensityâ€modulated radiotherapy (IMRT) technique. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 211-219.	1.8	7
72	Progress towards Patient-Specific, Spatially-Continuous Radiobiological Dose Prescription and Planning in Prostate Cancer IMRT: An Overview. Cancers, 2020, 12, 854.	3.7	7

#	Article	IF	Citations
73	Artificial intelligence in medical imaging and radiation oncology: Opportunities and challenges. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 481-485.	1.8	7
74	Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial. Physics in Medicine and Biology, 2021, 66, 195008.	3.0	7
75	Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial. Radiation Oncology, 2014, 9, 282.	2.7	6
76	On the use of a convolution–superposition algorithm for plan checking in lung stereotactic body radiation therapy. Journal of Applied Clinical Medical Physics, 2016, 17, 99-110.	1.9	6
77	Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the <scp>TROG</scp> 03.04 <scp>RADAR</scp> trial. Journal of Medical Imaging and Radiation Oncology, 2018, 62, 248-255.	1.8	6
78	Evaluation of EBT radiochromic film using a multiple exposure technique. Australasian Physical and Engineering Sciences in Medicine, 2011, 34, 281-289.	1.3	5
79	Lack of backscatter factor measurements in HDR applications with MOSkins. Australasian Physical and Engineering Sciences in Medicine, 2011, 34, 545-552.	1.3	5
80	Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. Journal of Medical Radiation Sciences, 2015, 62, 99-107.	1.5	5
81	Technical quality assurance during the <scp>TROG</scp> 03.04 <scp>RADAR</scp> prostate radiotherapy trial: Are the results reflected in observed toxicity rates?. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 99-108.	1.8	5
82	Will COVID-19 change the way we teach medical physics post pandemic?. Physical and Engineering Sciences in Medicine, 2020, 43, 735-738.	2.4	5
83	Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. Radiotherapy and Oncology, 2020, 150, 281-292.	0.6	5
84	Stereotactic ablative body radiation therapy (SABR) in NSW. Physical and Engineering Sciences in Medicine, 2020, 43, 641-650.	2.4	5
85	Brachytherapy: a dying art or missed opportunity?. Australasian Physical and Engineering Sciences in Medicine, 2016, 39, 5-9.	1.3	4
86	Patient specific quality control for Stereotactic Ablative Body Radiotherapy (SABR): it takes more than one phantom. Journal of Physics: Conference Series, 2017, 777, 012017.	0.4	4
87	Women and men in the Australasian College of Physical Scientists and Engineers in Medicine: workforce survey. Australasian Physical and Engineering Sciences in Medicine, 2019, 42, 33-41.	1.3	4
88	Ensemble Prostate Tumor Classification in H& E Whole Slide Imaging via Stain Normalization and Cell Density Estimation. Lecture Notes in Computer Science, 2015, , 280-287.	1.3	4
89	Interfraction patient motion and implant displacement in prostate high dose rate brachytherapy. Medical Physics, 2011, 38, 5838-5843.	3.0	3
90	Performance assessment of automated tissue characterization for prostate H and E stained histopathology. Proceedings of SPIE, 2015, , .	0.8	3

#	Article	IF	Citations
91	High dose rate brachytherapy source measurement intercomparison. Australasian Physical and Engineering Sciences in Medicine, 2017, 40, 377-383.	1.3	3
92	Radiobiological parameters in a tumour control probability model for prostate cancer LDR brachytherapy. Physics in Medicine and Biology, 2018, 63, 135011.	3.0	3
93	Use of deformable image registration techniques to estimate dose to organs at risk following prostate external beam radiation therapy and high-dose-rate brachytherapy. Journal of Contemporary Brachytherapy, 2021, 13, 72-79.	0.9	3
94	Artificial intelligence and imaging biomarkers for prostate radiation therapy during and after treatment. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 612-626.	1.8	3
95	Current status of intra-cranial stereotactic radiotherapy and stereotactic radiosurgery in Australia and New Zealand: key considerations from a workshop and surveys. Physical and Engineering Sciences in Medicine, 2022, 45, 251-259.	2.4	3
96	lodine-125 brachytherapy for prostate cancer: First published Australian experience. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 181-187.	0.6	2
97	Megavoltage versus kilovoltage image guidance for efficiency and accuracy in head and neck IMRT. Journal of Radiotherapy in Practice, 2009, 8, 177-184.	0.5	2
98	Tools to analyse and display variations in anatomical delineation. Australasian Physical and Engineering Sciences in Medicine, 2012, 35, 159-164.	1.3	2
99	Two non-parametric methods for derivation of constraints from radiotherapy dose–histogram data. Physics in Medicine and Biology, 2014, 59, N101-N111.	3.0	2
100	Testing the <scp>A</scp> ssessment of <scp>N</scp> ew <scp>R</scp> adiation <scp>O</scp> ncology <scp>T</scp> echnology and <scp>T</scp> reatments framework using the evaluation of postâ€prostatectomy radiotherapy techniques. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 129-137.	1.8	2
101	The Importance of Quasi-4D Path-Integrated Dose Accumulation for More Accurate Risk Estimation in Stereotactic Liver Radiotherapy. Technology in Cancer Research and Treatment, 2016, 15, 428-436.	1.9	2
102	Prostate cancer focal brachytherapy: Improving treatment plan robustness using a convolved dose rate model. Procedia Computer Science, 2017, 108, 1522-1531.	2.0	2
103	Clinical Application of Pre-Treatment Image Verification of Catheter Positions for HDR Prostate Brachytherapy. Brachytherapy, 2017, 16, S114-S115.	0.5	2
104	Automatic 3D modelling for prostate cancer brachytherapy. , 2017, , .		2
105	Derivation and representation of dose-volume response from large clinical trial data sets: an example from the RADAR prostate radiotherapy trial. Journal of Physics: Conference Series, 2014, 489, 012090.	0.4	1
106	An MLE method for finding LKB NTCP model parameters using Monte Carlo uncertainty estimates. Journal of Physics: Conference Series, 2014, 489, 012087.	0.4	1
107	Which patients benefit from postâ€implant <scp>CT</scp> dosimetry after realâ€time intraoperative planning for <scp>LDR</scp> prostate brachytherapy: Should intraoperatively planned patients be treated differently?. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 244-246.	1.8	1
108	SU-E-T-509: DICOM Test Case Plans for Model-Based Dose Calculations Methods in Brachytherapy. Medical Physics, 2013, 40, 322-322.	3.0	1

#	Article	IF	CITATIONS
109	In Regard to Shortall et al. International Journal of Radiation Oncology Biology Physics, 2022, 112, 831-833.	0.8	1
110	Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. Physics and Imaging in Radiation Oncology, 2022, 22, 91-97.	2.9	1
111	Online Kidney Position Verification Using Non-Contrast Radiographs on a Linear Accelerator with on Board KV X-Ray Imaging Capability. Medical Dosimetry, 2009, 34, 293-300.	0.9	O
112	XVII International Conference on the Use of Computers in Radiation Therapy (ICCR 2013). Journal of Physics: Conference Series, 2014, 489, 011001.	0.4	0
113	Focal Brachytherapy Treatment Planning Using Multi-Parametric MRI and Biological Dose Optimisation. Brachytherapy, 2015, 14, S11-S12.	0.5	0
114	Identification of Catheter Displacements in HDR Prostate Brachytherapy Using a â€~Shift Image' Reconstruction Technique. Brachytherapy, 2017, 16, S106.	0.5	0
115	A pilot study on geometrical uncertainties for intra ocular cancers in radiotherapy. Australasian Physical and Engineering Sciences in Medicine, 2017, 40, 433-439.	1.3	O
116	Use of contemporary prostate brachytherapy approaches in clinical trials. Journal of Physics: Conference Series, 2019, 1154, 012010.	0.4	0
117	Low-dose-rate iodine-125 seed air kerma strength measurement intercomparison. Brachytherapy, 2020, 19, 119-125.	0.5	0
118	TU-G-108-06: Anatomical Localization of Late Rectal Toxicity Predictors in Prostate Radiotherapy. Medical Physics, 2013, 40, 454-454.	3.0	O